Edesa Biotech, Inc.

NasdaqCM:EDSA Stock Report

Market Cap: US$6.3m

Edesa Biotech Management

Management criteria checks 4/4

Edesa Biotech's CEO is Par Nijhawan, appointed in Jun 2019, has a tenure of 5.5 years. total yearly compensation is $464.73K, comprised of 77% salary and 23% bonuses, including company stock and options. directly owns 14% of the company’s shares, worth $878.52K. The average tenure of the management team and the board of directors is 5.5 years and 5.5 years respectively.

Key information

Par Nijhawan

Chief executive officer

US$464.7k

Total compensation

CEO salary percentage77.0%
CEO tenure5.5yrs
CEO ownership14.0%
Management average tenure5.5yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Aug 04
Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Mar 10
We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Sep 30

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Sep 23
Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa says mid-stage trial for anti-allergic cream reached full enrollment

Sep 07

Edesa Biotech GAAP EPS of -$0.37 beats by $0.06

Aug 12

Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

May 16
Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Apr 18

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Dec 08
Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Sep 22

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Aug 27
Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Jun 18

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Apr 13
Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Feb 19
Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Edesa Biotech receives C$14M for COVID-19 study

Feb 02

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Dec 08
Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa Biotech EPS misses by $0.04, beats on revenue

Dec 07

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

Nov 03

CEO Compensation Analysis

How has Par Nijhawan's remuneration changed compared to Edesa Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024US$465kUS$358k

-US$6m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$7m

Dec 31 2023n/an/a

-US$8m

Sep 30 2023US$550kUS$341k

-US$8m

Jun 30 2023n/an/a

-US$9m

Mar 31 2023n/an/a

-US$13m

Dec 31 2022n/an/a

-US$16m

Sep 30 2022US$602kUS$326k

-US$18m

Jun 30 2022n/an/a

-US$18m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021n/an/a

-US$15m

Sep 30 2021US$1mUS$315k

-US$13m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020n/an/a

-US$8m

Sep 30 2020US$411kUS$300k

-US$6m

Jun 30 2020n/an/a

-US$5m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019n/an/a

-US$4m

Sep 30 2019US$165kUS$105k

-US$3m

Jun 30 2019n/an/a

-US$3m

Mar 31 2019n/an/a

-US$2m

Dec 31 2018US$61kUS$27k

-US$2m

Compensation vs Market: Par's total compensation ($USD464.73K) is about average for companies of similar size in the US market ($USD650.40K).

Compensation vs Earnings: Par's compensation has been consistent with company performance over the past year.

CEO

Par Nijhawan (54 yo)

5.5yrs

Tenure

US$464,728

Compensation

Dr. Pardeep Nijhawan, M.D., FRCPC, AGAF, also known as Par, serves as Chief Executive Officer, Company secretary and Director at Edesa Biotech, Inc. since June 7, 2019 and having previously founded and led...

Leadership Team

NamePositionTenureCompensationOwnership
Pardeep Nijhawan
CEO, Company Secretary & Director5.5yrsUS$464.73k14%
$ 878.5k
Michael Brooks
President5.5yrsUS$428.99k0.13%
$ 7.9k
Stephen Lemieux
Chief Financial Officer1.4yrsUS$368.10k0.17%
$ 10.4k

5.5yrs

Average Tenure

48yo

Average Age

Experienced Management: EDSA's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Pardeep Nijhawan
CEO, Company Secretary & Director5.5yrsUS$464.73k14%
$ 878.5k
Joan Chypyha
Independent Director1.6yrsUS$51.50k0.00084%
$ 52.7
Sean MacDonald
Independent Director5.5yrsUS$35.00k0.059%
$ 3.7k
Charles Olson
Independent Director1.6yrsUS$44.00k0.075%
$ 4.7k
Frank Oakes
Independent Director14.7yrsUS$48.50k0.34%
$ 21.1k
Patrick Marshall
Independent Director1.6yrsUS$47.00k0.013%
$ 841.7
Carlo Sistilli
Independent Chairman of the Board5.5yrsUS$65.00k0.015%
$ 944.6

5.5yrs

Average Tenure

57yo

Average Age

Experienced Board: EDSA's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 15:53
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Edesa Biotech, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vernon BernardinoH.C. Wainwright & Co.
David BautzZacks Small-Cap Research